Lupin gained 2.91% to Rs 702.45 at 12:19 IST on BSE after the company said it has received a final approval from US Food and Drug Administration for its abbreviated new drug application for ramipril capsules in multiple strengths.
The company has an equity capital of Rs 82.08 crore. Face value per share is Rs 10.
The current price of Rs 702.45 discounts its Q4 March 2008 annualised EPS of Rs 37.35, by a PE multiple of 18.81.
Ramipril capsule are the AB rated generic equivalent of King Pharmaceuticals' Altace capsule, indicated for the treatment of hypertension. It had annual sales of $920 million for the year ended December 2007, based on IMS Health sales data.
On 30 May 2008, Lupin got tentative approval from the US Food and Drug Administration to make and market multiple strengths of topiramate tablets.
On 15 May 2008, Lupin Pharmaceuticals Inc, a unit of Lupin received tentative approval from US Food and Drug Administration for ramipril capsules.
In April 2008, Lupin’s subsidiary in Japan, Kyowa Pharmaceutical Industry Co, received approvals from the country's ministry of health and labour welfare for 10 products.
Lupin’s net profit declined 44% to Rs 76.64 crore on 19.6% increase in net sales to Rs 619.57 crore in Q4 March 2008 over Q4 March 2007.
Lupin is engaged in manufacturing active pharmaceutical ingredients and formulations.
The current price of Rs 702.45 discounts its Q4 March 2008 annualised EPS of Rs 37.35, by a PE multiple of 18.81.
Ramipril capsule are the AB rated generic equivalent of King Pharmaceuticals' Altace capsule, indicated for the treatment of hypertension. It had annual sales of $920 million for the year ended December 2007, based on IMS Health sales data.
On 30 May 2008, Lupin got tentative approval from the US Food and Drug Administration to make and market multiple strengths of topiramate tablets.
On 15 May 2008, Lupin Pharmaceuticals Inc, a unit of Lupin received tentative approval from US Food and Drug Administration for ramipril capsules.
In April 2008, Lupin’s subsidiary in Japan, Kyowa Pharmaceutical Industry Co, received approvals from the country's ministry of health and labour welfare for 10 products.
Lupin’s net profit declined 44% to Rs 76.64 crore on 19.6% increase in net sales to Rs 619.57 crore in Q4 March 2008 over Q4 March 2007.
Lupin is engaged in manufacturing active pharmaceutical ingredients and formulations.
0 comments:
Post a Comment